Laura Biganzoli
机构：Azienda Usl Toscana Centro, Hospital of Prato · ORCID：0000-0001-7989-8658
发表论文 473 篇 · 总被引 21039 次 · h-index 66
代表论文
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024 · New England Journal of Medicine · 被引 440)
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 (2024 · Journal of Clinical Oncology · 被引 166)
- Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) (2024 · Journal of Clinical Oncology · 被引 34)
- Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients (2024 · Future Oncology · 被引 11)
- Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial (2024 · Nature Medicine · 被引 8)
- Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer (2025 · npj Breast Cancer · 被引 7)